BioNTech inventory falls after CureVac information swimsuit, saying COVID vaccine infringes patents


Share post:

Shares of BioNTech SE

fell 0.9% in premarket buying and selling Tuesday, after CureVac N.V.

filed in Germany a patent infringement swimsuit in opposition to the biotechnology firm. CureVac stated there have been sure of its patents that had been utilized within the manufacture and sale of BioNTech and Pfizer Inc.’s COVID-19 vaccine, Comirnaty. CureVac stated whereas it does not search an injunction, and will not take authorized motion to impede the manufacturing or sale of Comirnaty, it’s searching for “truthful compensation” for infringement of its patents. CureVac’s inventory rose 0.4% in premarket buying and selling, and Pfizer shares slipped 0.8%. 12 months up to now, CureVac’s inventory has tumbled 58.5% and BioNTech shares have shed 38.9%, whereas the iShares Biotechnology ETF

has dropped 21.3% and the S&P 500

has shed 19.7%.


Please enter your comment!
Please enter your name here


Related articles

The Benefits of a Creative Subscription with Envato Elements

If you’re looking to find and use royalty-free images and other creative resources, it can be tough to...

Get an Additional ₹100 Cashback When You Pay with Domino’s Digital Wallet Partners

How does ₹100 cashback sound? Find out more about the additional cashback you can get when you pay...

Get Unlimited Access to DataCamp’s Library of Online Courses

DataCamp subscriptions enable access to over 300 courses, as well as projects, assessments, and additional content. Whether you're...

Why You Should Buy from DaMENSCH: The Best in Quality, Service, and Value

Buying products online can be dangerous; you never know if you’re getting an authentic product, or one that’s...